Literature DB >> 8618235

Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.

M Ferrarini1, S Heltai, S M Pupa, S Mernard, R Zocchi.   

Abstract

BACKGROUND: The monomeric laminin receptor, a 67-kd high-affinity laminin-binding protein, is expressed by a variety of normal cell types. Overexpression and abnormal surface distribution of this receptor have been demonstrated in tumor cells where it appears to promote tumor invasion and metastasis. Previously, we reported the existence of an association between laminin receptor overexpression by lung cancer cells and the presence of tumor-infiltrating lymphocytes (TILs) bearing gammadelta T-cell receptors. Gammadelta(+) lymphocytes represents a sizable fraction of the TILs in approximately one fourth of lung cancers analyzed thus far.
PURPOSE: The aim of this study was to determine whether gammadelta(+) TILs might participate in the immune response against lung cancer through recognition of monomeric laminin receptors expressed by tumor cells.
METHODS: Tumor cells from 11 lung cancer specimens exhibiting sizable gammadelta(+) T-cell infiltrates and from 11 other specimens infiltrated predominantly by lymphocytes bearing alphabeta(+) T-cell receptors were analyzed for expression of the monomeric laminin receptor by use of the monoclonal antibody (MAb) MLuC5. Gammadalta TILs and chibeta+ TILs derived from four tumors were each examined for cytotoxic activity toward lung cancer target cells by use of a standard 51Cr-release assay and lung tumor cell lines expressing different levels of surface monomeric laminin receptor. The ability of MAbs directed against the laminin receptor (i.e., MLuC5) or against gammadelta T-cell receptors (i.e., TigammaA and A13) as well as laminin peptides known to bind to the laminin receptor to inhibit TIL-mediated target cells lysis was also determined.
RESULTS: We confirmed that the association between overexpression of the monomeric laminin receptor by lung tumor cells and the presence of gammadeltadelta+ TILs is statistically significant (two sided P = .003; Fisher's exact test). We also observed a relationship between the levels of laminin receptor expression on cultured lung cancer cells and their susceptibility to specific lysis by gammadelta(+), but not alphabeta+, TILs. This specific cell killing was not T-cell receptor mediated, but it was inhibited by addition of the anti-monomeric laminin receptor MAb MLuC5 and by a synthetic peptide corresponding to amino acids 2091-2108 of the laminin A chain. CONCLUSION AND IMPLICATIONS: Our results indicate gammadelta(+) TILs localized at human lung cancer sites can kill tumor cells in a process that involves interaction with the monomeric laminin receptor. The infiltration of gammadelta(+) TILs at lung tumor sites may represent a first line of defense against cells undergoing malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618235     DOI: 10.1093/jnci/88.7.436

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

Review 1.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

2.  Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer.

Authors:  Mohammed Elimam Ahamed Mohammed; Nuha Mohammed Elhassan
Journal:  J Int Med Res       Date:  2019-10-11       Impact factor: 1.671

Review 3.  γδ T-cell immunotherapy for lung cancer.

Authors:  Yukihiro Yoshida; Jun Nakajima; Hiromi Wada; Kazuhiro Kakimi
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

4.  Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.

Authors:  Shannon D McClintock; Roscoe L Warner; Saqib Ali; Apurupa Chekuri; Michael K Dame; Durga Attili; Randall K Knibbs; Muhammad Nadeem Aslam; Joseph Sinkule; Alton Charles Morgan; Adel Barsoum; Lauren B Smith; David G Beer; Kent J Johnson; James Varani
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 5.  γδ T cell therapy for the treatment of non-small cell lung cancer.

Authors:  Kazuhiro Kakimi; Hirokazu Matsushita; Tomohiro Murakawa; Jun Nakajima
Journal:  Transl Lung Cancer Res       Date:  2014-02

6.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

Review 7.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

8.  Identification and Validation of Immune-Related Gene Signature for Predicting Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma.

Authors:  Ran Jia; Zhilin Sui; Hongdian Zhang; Zhentao Yu
Journal:  Front Mol Biosci       Date:  2021-05-24

Review 9.  Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation.

Authors:  Lionel Couzi; Vincent Pitard; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Front Immunol       Date:  2015-01-21       Impact factor: 7.561

Review 10.  Human gamma delta T cells: candidates for the development of immunotherapeutic strategies.

Authors:  Susann Beetz; Lothar Marischen; Dieter Kabelitz; Daniela Wesch
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.